FI86546B - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara spergualinderivat. - Google Patents

Foerfarande foer framstaellning av nya terapeutiskt anvaendbara spergualinderivat. Download PDF

Info

Publication number
FI86546B
FI86546B FI871445A FI871445A FI86546B FI 86546 B FI86546 B FI 86546B FI 871445 A FI871445 A FI 871445A FI 871445 A FI871445 A FI 871445A FI 86546 B FI86546 B FI 86546B
Authority
FI
Finland
Prior art keywords
group
protected
leu
phg
boc
Prior art date
Application number
FI871445A
Other languages
English (en)
Finnish (fi)
Other versions
FI871445A (fi
FI86546C (sv
FI871445A0 (fi
Inventor
Hamao Umezawa
Tomio Takeuchi
Tetsushi Saino
Masao Yoshida
Katsutoshi Takahashi
Teruya Nakamura
Original Assignee
Microbial Chem Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbial Chem Res Found filed Critical Microbial Chem Res Found
Publication of FI871445A0 publication Critical patent/FI871445A0/fi
Publication of FI871445A publication Critical patent/FI871445A/fi
Application granted granted Critical
Publication of FI86546B publication Critical patent/FI86546B/fi
Publication of FI86546C publication Critical patent/FI86546C/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Train Traffic Observation, Control, And Security (AREA)
  • Electric Propulsion And Braking For Vehicles (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (7)

1. Förfarande för framställning av nya terapeu-tiskt användbara spergualinderivat med formeln (I) och 5 farmakologiskt godtagbara salter därav, R R H2N\ I fl HN^c-NH-X-(CH2>3-CONHCHCONH-(CH2)4-i,-(CH2)3-NH-S2 (I) 10 i vilken formel X är -(CH2)3_5 eller · r är -H eller -CH20H; nh2 nh_ —e— | | *
15 Rx är -H, ^J^-CH-CO- eller (CH3) 2CHCS2-CH-CO- ; R2 är 1. en grupp med formeln
20 V* Γ2 „-ch-=o- X2 25 där n är 0 eller 1; X2 är -H eller -OH; och X2 är -H eller -CH20H, x I 4 2. en grupp med formeln x _(CH ) -CH-CO- 3 2 'm där m är ett hei tai 0-4; X3 är -H, -COOH, -OH, -NH2 eller 30 -C0NH2; X4 är -H eller -NH2; och ätminstone den ena av X3 och X4 är -NH2, 3. en grupp med formeln H-( A)y- CH2CH( CHj )2 35 där y är 1 eller 2; A är _NH_<i.H_c0_ 73 86 5 4 6 C^-CO-; eller [ ; och dA y dr 2, bildar tvA A-grupper en peptidbindning, eller 5 4) en grupp med formeIn ^^-CH2-CH - CH-CO-nh2 OH 10 och dA R2 är en annan grupp dn -H, dr R2 sanuna som R2, kdnnetecknat därav, att man avlägsnar skyddsgrupperna frAn en förening med formeln (II), som innehAller skyddsgrupper,
15. I1 ?« HN^ -x-(CH2)3-CONHCHCONH-(ca2)4-N-(CH2)3-NH-R5 <«> ddr X betecknar samma som ovan; R3 är -H eller -CH2-0-Y, där Y är -H eller en hydroxiskyddsgrupp; R4 dr -H, en fe-20 nylglycylgrupp, ddr amlnogruppen dr skyddad, eller en leucylgrupp, ddr amlnogruppen dr skyddad; och R5 dr en rest, som motsvarar R2-gruppen, ddr amlnogruppen dr skyddad; och dA R4 dr en fenylglycyl- eller leucylgrupp, ddr amlnogruppen dr skyddad, dr R5 en fenyl- eller leucyl-25 grupp, ddr amlnogruppen dr skyddad.
2. Förfarande enligt patentkravet I, kännetecknat därav, att R2 dr (L eller D) ^H2 -Q-c a-co-, nh2 30. eller (L,L)—(CH,)0CHCH-CHCONHCH-CO-. (L)-(CH3)2chch2ch-co-, 32 2l I NH2 CH2CH(CH3)2 Förfarande för framstdllnlng av 10-{N-[4-(4- (guanidlnofenyl)butanoyl]-L-seryl}-l-L- eller D-fenylgly-35 cyl-1,5,10-triazadekan eller ett farmakologiskt godtag- 74 86 546 bart salt därav, kännetecknat därav, att man avlägsnar skyddsgrupperna frän 10-{N-[4-(4-guanidinofe-nyl)butanoyl]-L-seryl}-l-N-skyddad-L- eller D-fenylgly-cyl-1,5,10-triazadekan eller ett sait därav. 5 4. Förfarande för framställning av 10-{N-[4-(4- (guanidinofenyl)butanoyl]-L-seryl}-l-L-leucyl-l,5,10-trlazadekan eller ett farmakologiskt godtagbart sait därav, kännetecknat därav, att man avlägsnar skyddsgrupperna frän 10-{N-[4-(4-guanidinofenyl)buta-10 noyl]-L-seryl}-l-N-skyddad-L- eller D-leucyl-1,5,10-triazadekan eller ett sait därav.
5. Förfarande för framställning av 10-{N-[4-(4-(guanidinofenyl)butanoyl]seryl}-1-L-leucy1-L-leucyl- 1.5.10- triazadekan eller ett farmakologiskt godtagbart 15 sait därav, kännetecknat därav, att man avlägsnar skyddsgrupperna frän 10-{N-[4-(4-guanidinofenyl)-butanoyl]-L-seryl}-l-N-skyddad-L-leucyl-L-leucyl-l,5,10-triazadekan eller ett sait därav.
6. Förfarande för framställning av 10-{N-[4-(4- 20 guanidinofenyl)butanoyl]-L-seryl}-l,5-di-L-fenylglycyl- 1.5.10- triazadekan eller ett farmakologiskt godtagbart sait därav, kännetecknat därav, att man avlägsnar skyddsgrupperna frän 10-{N-[4-(4-guanidinofenyl)-butanoyl]-0-bensyl-L-seryl}-l,5-di-N-skyddad-L-fenylgly- 25 cyl-1,5,10-triazadekan eller ett sait därav.
FI871445A 1986-04-04 1987-04-02 Förfarande för framställning av nya terapeutiskt användbara spergualin derivat FI86546C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7774786 1986-04-04
JP7774786 1986-04-04

Publications (4)

Publication Number Publication Date
FI871445A0 FI871445A0 (fi) 1987-04-02
FI871445A FI871445A (fi) 1987-10-05
FI86546B true FI86546B (fi) 1992-05-29
FI86546C FI86546C (sv) 1992-09-10

Family

ID=13642505

Family Applications (1)

Application Number Title Priority Date Filing Date
FI871445A FI86546C (sv) 1986-04-04 1987-04-02 Förfarande för framställning av nya terapeutiskt användbara spergualin derivat

Country Status (17)

Country Link
US (1) US4956504A (sv)
EP (1) EP0241797B1 (sv)
JP (1) JPH0745460B2 (sv)
KR (2) KR940006768B1 (sv)
CN (1) CN1016341B (sv)
AT (1) ATE64378T1 (sv)
AU (1) AU599092B2 (sv)
CA (1) CA1305827C (sv)
DE (1) DE3770680D1 (sv)
DK (2) DK171487A (sv)
ES (1) ES2039213T3 (sv)
FI (1) FI86546C (sv)
GR (1) GR3002660T3 (sv)
HU (1) HU204069B (sv)
IE (1) IE60077B1 (sv)
PT (1) PT84620B (sv)
ZA (1) ZA872440B (sv)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0794424B2 (ja) * 1987-09-30 1995-10-11 財団法人微生物化学研究会 新スパガリン関連化合物およびその製造法
US5770625A (en) * 1988-02-08 1998-06-23 The Trustees Of Columbia University In The City Of New York Butyryl-tyrosinyl spermine, analogs thereof and methods of preparing and using same
US4990536A (en) * 1989-04-03 1991-02-05 Nippon Kayaku Kabushiki Kaisha Immunopotentiator and spergualin-related compound therefor
YU48230B (sh) * 1989-05-29 1997-08-22 Takara Shuzo Co.Ltd. Kristalni deoksispergvalin i postupak za njegovo pripremanje
US5086069A (en) * 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
DE69104291T2 (de) * 1990-07-20 1995-05-18 Nippon Kayaku Kk Spergulinähnliche Verbindungen und ihre Verwendung.
JPH08503920A (ja) * 1991-04-11 1996-04-30 ローヌ−プーラン ローラー インターナショナル(ホウルディングス) インコーポレイテッド 抗血栓ペプチドおよび偽ペプチド誘導体
WO1994004140A1 (en) * 1992-08-19 1994-03-03 Nippon Kayaku Kabushiki Kaisha Antiprotozoan drug
FR2698628B1 (fr) * 1992-12-02 1995-02-17 Fournier Ind & Sante Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
GB9726569D0 (en) * 1997-12-16 1998-02-11 Univ Southampton Neuroprotective agents
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
KR100604206B1 (ko) * 2005-12-01 2006-07-24 박현미 배선용 단자

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5748957A (en) * 1980-09-08 1982-03-20 Microbial Chem Res Found Novel antibiotic bmg 162-af2, its preparation and carcinostatic agent comprising it as active ingredient
JPS57185254A (en) * 1981-05-11 1982-11-15 Microbial Chem Res Found Novel carcinostatic substances and their preparation
JPS5862152A (ja) * 1981-10-08 1983-04-13 Microbial Chem Res Found N−〔4−(3−アミノプロピル)アミノブチル〕−2−(ω−グアニジノ脂肪酸アミド)−2−ヒドロキシエタンアミドおよびその誘導体ならびにその製造法
JPS5942356A (ja) * 1982-09-02 1984-03-08 Microbial Chem Res Found スパガリン関連化合物およびその製造法
US4525299A (en) * 1983-05-10 1985-06-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai (-)-15-Deoxyspergualin, process for the preparation thereof, and intermediate of the same
JPS60104099A (ja) * 1983-11-09 1985-06-08 Nippon Kayaku Co Ltd スパガリン関連化合物の新規製造法
JPS60181056A (ja) * 1984-02-29 1985-09-14 Takara Shuzo Co Ltd Ν−〔4−(3−アミノプロピル)アミノブチル〕−2,2−ジヒドロキシエタンアミドの製造法
JPS60185758A (ja) * 1984-03-02 1985-09-21 Microbial Chem Res Found フエニレン基を有するスパガリン関連化合物およびその製造法
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
AU587691B2 (en) * 1987-03-30 1989-08-24 Shosuke Okamoto Phenylalanine derivative and proteinase inhibitor

Also Published As

Publication number Publication date
JPS6345247A (ja) 1988-02-26
CN1016341B (zh) 1992-04-22
KR940007743B1 (ko) 1994-08-24
FI871445A (fi) 1987-10-05
CN87102538A (zh) 1987-11-18
JPH0745460B2 (ja) 1995-05-17
AU7107587A (en) 1987-10-08
DK102792A (da) 1992-08-18
KR940006768B1 (ko) 1994-07-27
HU204069B (en) 1991-11-28
DK171487D0 (da) 1987-04-03
EP0241797B1 (en) 1991-06-12
DK171487A (da) 1987-10-05
KR870009989A (ko) 1987-11-30
PT84620B (pt) 1989-11-30
US4956504A (en) 1990-09-11
EP0241797A2 (en) 1987-10-21
KR890001965A (ko) 1989-04-06
GR3002660T3 (en) 1993-01-25
FI86546C (sv) 1992-09-10
ATE64378T1 (de) 1991-06-15
DE3770680D1 (de) 1991-07-18
CA1305827C (en) 1992-07-28
HUT44577A (en) 1988-03-28
FI871445A0 (fi) 1987-04-02
AU599092B2 (en) 1990-07-12
IE60077B1 (en) 1994-06-01
DK102792D0 (da) 1992-08-18
ES2039213T3 (es) 1993-09-16
IE870864L (en) 1987-10-04
ZA872440B (en) 1987-12-30
PT84620A (en) 1987-05-01
EP0241797A3 (en) 1988-07-20

Similar Documents

Publication Publication Date Title
FI56676C (fi) Foerfarande foer framstaellning av nya amidderivat av nonapeptid som befraemjar loesgoerandet av aeggceller
AU669064B2 (en) Urethanes and ureas that induce cytokine production
FI86546B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara spergualinderivat.
CA1312702C (en) Oligopeptidyl nitrile derivatives, agents containing them, a process for their preparation, and their use
KR20110022594A (ko) 신규한 이중 표적화 항종양성 접합체
DE3783280T2 (de) Teilweise retro-invertierte analoge des tuftsin, methode zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
FI79329B (fi) Nytt foerfarande foer framstaellning av pentapeptiden h-arg-x-asp-y-tyr-r och vid foerfarandet anvaenda mellanprodukter.
EP0721447B1 (en) Anthracene derivatives for use as anticancer agent or dye
AU744425B2 (en) 20(s) camptothecin glycoconjugates
NZ250653A (en) Somatostatin derivatives and pharmaceutical or diagnostic imaging compositions
KR100405009B1 (ko) 바이싸이클릭타치키닌길항제,그의약제,및약제학적조성물로사용하는그의용도
WO1995020603A1 (en) Inhibitors of serine proteases, bearing a chelating group
WO1993000359A1 (en) Modified peptides transportable into the central nervous system
EP0295316A2 (en) Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones
Thierry et al. Synthesis and activity of NAcSerAspLysPro analogs on cellular interactions between T-cell and erythrocytes in rosette formation
EP0309971A2 (en) New spergualin-related compound and pharmaceutical composition
EP0604957A1 (en) 2-Amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
ES2203934T3 (es) Compuestos monociclicos con cuatro restos bifuncionales que tienen accon antagonista en nk-2.
EP1864994B1 (en) Par-2 agonist
Nishikawa et al. Synthesis and biological properties of partially modified retro and retro-inverso pseudo peptides of Arg-Gly-Asp (RGD)
EP0672678A1 (en) Azapeptide derivative
Oiry et al. Synthesis and radioprotective activity of dipeptide cysteamine and cystamine derivatives
KR790001842B1 (ko) 신규 폴리펩티드의 제조법
CA2128552A1 (en) Derivatives of 6,7-dihydroxy-4-thiaheptanoic acid and their use
GB1568195A (en) Synthetc peptides

Legal Events

Date Code Title Description
MM Patent lapsed
MM Patent lapsed

Owner name: MICROBIAL CHEMISTRY RESEARCH FOUNDATION